EE200200622A - Aromataasi inhibiitori kasutamine farmatseutilisekompositsiooni valmistamiseks, mis on ette nähtudHER2 valgu liigse avaldumisega hormoon-sõltuva häire raviks, ja meetod vähivastase ravi kõrvaltoimete vähendamiseks - Google Patents
Aromataasi inhibiitori kasutamine farmatseutilisekompositsiooni valmistamiseks, mis on ette nähtudHER2 valgu liigse avaldumisega hormoon-sõltuva häire raviks, ja meetod vähivastase ravi kõrvaltoimete vähendamiseksInfo
- Publication number
- EE200200622A EE200200622A EEP200200622A EEP200200622A EE200200622A EE 200200622 A EE200200622 A EE 200200622A EE P200200622 A EEP200200622 A EE P200200622A EE P200200622 A EEP200200622 A EE P200200622A EE 200200622 A EE200200622 A EE 200200622A
- Authority
- EE
- Estonia
- Prior art keywords
- overexpression
- hormone
- preparation
- reducing
- treatment
- Prior art date
Links
- 229940122815 Aromatase inhibitor Drugs 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 238000011319 anticancer therapy Methods 0.000 title 1
- 239000003886 aromatase inhibitor Substances 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000002018 overexpression Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57135500A | 2000-05-15 | 2000-05-15 | |
| PCT/EP2001/004468 WO2001087334A1 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200200622A true EE200200622A (et) | 2004-06-15 |
Family
ID=24283360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200622A EE200200622A (et) | 2000-05-15 | 2001-04-19 | Aromataasi inhibiitori kasutamine farmatseutilisekompositsiooni valmistamiseks, mis on ette nähtudHER2 valgu liigse avaldumisega hormoon-sõltuva häire raviks, ja meetod vähivastase ravi kõrvaltoimete vähendamiseks |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1282440A1 (et) |
| JP (1) | JP2003533490A (et) |
| KR (1) | KR20030014223A (et) |
| CN (1) | CN1429118A (et) |
| AU (1) | AU784617B2 (et) |
| BR (1) | BR0110732A (et) |
| CA (1) | CA2409652A1 (et) |
| CZ (1) | CZ20023748A3 (et) |
| EA (1) | EA005931B1 (et) |
| EE (1) | EE200200622A (et) |
| HK (1) | HK1054200A1 (et) |
| HU (1) | HUP0301877A2 (et) |
| IL (1) | IL152389A0 (et) |
| MX (1) | MXPA02011194A (et) |
| NO (1) | NO20025302L (et) |
| NZ (1) | NZ523004A (et) |
| PL (1) | PL360153A1 (et) |
| SK (1) | SK16022002A3 (et) |
| WO (1) | WO2001087334A1 (et) |
| ZA (1) | ZA200209815B (et) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| SI1282443T1 (sl) | 2000-05-19 | 2010-01-29 | Genentech Inc | Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB |
| MXPA03006607A (es) * | 2001-01-26 | 2003-09-22 | Upjohn Co | Metodo combinado para tratar trastornos dependientes de hormonas. |
| GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
| CN100424175C (zh) | 2002-03-26 | 2008-10-08 | 上海泽生科技开发有限公司 | ErbB-3 用于肿瘤治疗的方法和组合物 |
| EP1551452A4 (en) * | 2002-07-01 | 2006-08-30 | Savient Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| CN101014365B (zh) * | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
| RU2438705C2 (ru) | 2005-01-21 | 2012-01-10 | Дженентек, Инк. | Введение фиксированных доз her-антител |
| CA2596133C (en) | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| CA2626337C (en) | 2005-10-19 | 2015-12-29 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| AU2008223069B2 (en) | 2007-03-02 | 2012-12-13 | F. Hoffmann-La Roche Ag | Predicting response to a HER dimerisation inhibitor based on low HER3 expression |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| AU2010226453B2 (en) | 2009-03-20 | 2013-11-21 | Genentech, Inc. | Bispecific anti-HER antibodies |
| SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| WO2011103242A1 (en) | 2010-02-18 | 2011-08-25 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
| EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CN102068429B (zh) * | 2010-12-28 | 2011-12-14 | 西南大学 | 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法 |
| CN103890007A (zh) | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | 神经调节蛋白抗体及其用途 |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| KR20140098834A (ko) | 2011-11-30 | 2014-08-08 | 제넨테크, 인크. | 암에서의 erbb3 돌연변이 |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| AU2013240261A1 (en) | 2012-03-27 | 2014-09-18 | Genentech, Inc. | Diagnosis and treatments relating to HER3 inhibitors |
| US20160038490A1 (en) * | 2012-07-18 | 2016-02-11 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
| MX363188B (es) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1. |
| CN113633644A (zh) | 2014-10-22 | 2021-11-12 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
| WO2017066827A1 (en) | 2015-10-22 | 2017-04-27 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CN107417791B (zh) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双特异性抗体、其制备方法及用途 |
| WO2020243777A1 (en) | 2019-06-03 | 2020-12-10 | Havah Therapeutics Pty Ltd | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2001
- 2001-04-19 NZ NZ523004A patent/NZ523004A/en unknown
- 2001-04-19 BR BR0110732-1A patent/BR0110732A/pt not_active IP Right Cessation
- 2001-04-19 MX MXPA02011194A patent/MXPA02011194A/es not_active Application Discontinuation
- 2001-04-19 KR KR1020027015223A patent/KR20030014223A/ko not_active Ceased
- 2001-04-19 WO PCT/EP2001/004468 patent/WO2001087334A1/en not_active Ceased
- 2001-04-19 EE EEP200200622A patent/EE200200622A/et unknown
- 2001-04-19 HU HU0301877A patent/HUP0301877A2/hu unknown
- 2001-04-19 EA EA200201213A patent/EA005931B1/ru not_active IP Right Cessation
- 2001-04-19 CA CA002409652A patent/CA2409652A1/en not_active Abandoned
- 2001-04-19 JP JP2001583801A patent/JP2003533490A/ja not_active Withdrawn
- 2001-04-19 IL IL15238901A patent/IL152389A0/xx unknown
- 2001-04-19 SK SK1602-2002A patent/SK16022002A3/sk not_active Application Discontinuation
- 2001-04-19 CZ CZ20023748A patent/CZ20023748A3/cs unknown
- 2001-04-19 EP EP01929585A patent/EP1282440A1/en not_active Withdrawn
- 2001-04-19 PL PL36015301A patent/PL360153A1/xx not_active Application Discontinuation
- 2001-04-19 CN CN01809581A patent/CN1429118A/zh active Pending
- 2001-04-19 HK HK03106504.3A patent/HK1054200A1/zh unknown
- 2001-04-19 AU AU56309/01A patent/AU784617B2/en not_active Ceased
-
2002
- 2002-11-05 NO NO20025302A patent/NO20025302L/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209815A patent/ZA200209815B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1282440A1 (en) | 2003-02-12 |
| HK1054200A1 (zh) | 2003-11-21 |
| PL360153A1 (en) | 2004-09-06 |
| CN1429118A (zh) | 2003-07-09 |
| NO20025302D0 (no) | 2002-11-05 |
| ZA200209815B (en) | 2003-12-03 |
| IL152389A0 (en) | 2003-05-29 |
| AU5630901A (en) | 2001-11-26 |
| SK16022002A3 (sk) | 2003-04-01 |
| JP2003533490A (ja) | 2003-11-11 |
| NO20025302L (no) | 2002-11-05 |
| AU784617B2 (en) | 2006-05-18 |
| BR0110732A (pt) | 2003-02-04 |
| EA200201213A1 (ru) | 2003-04-24 |
| EA005931B1 (ru) | 2005-08-25 |
| KR20030014223A (ko) | 2003-02-15 |
| WO2001087334A1 (en) | 2001-11-22 |
| NZ523004A (en) | 2004-09-24 |
| HUP0301877A2 (hu) | 2003-09-29 |
| CA2409652A1 (en) | 2001-11-22 |
| CZ20023748A3 (cs) | 2003-04-16 |
| MXPA02011194A (es) | 2003-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200622A (et) | Aromataasi inhibiitori kasutamine farmatseutilisekompositsiooni valmistamiseks, mis on ette nähtudHER2 valgu liigse avaldumisega hormoon-sõltuva häire raviks, ja meetod vähivastase ravi kõrvaltoimete vähendamiseks | |
| AU7490700A (en) | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing | |
| WO2002005791A3 (en) | Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor | |
| EE04582B1 (et) | Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis | |
| EE200000770A (et) | Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks | |
| CY1107512T1 (el) | Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους | |
| DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
| ATE430570T1 (de) | Synergistische kombinationstherapie zur krebsbehandlung | |
| NZ617083A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| DK1034008T3 (da) | Dosisindstillende indretning til medicinske injektorer | |
| EE200000366A (et) | Seade ja meetod keha kudede ravimiseks elektri või ravimitega | |
| HUP0402661A3 (en) | Formulation and dosage form for the controlled delivery of therapeutic agents | |
| AUPR839001A0 (en) | Dosage form, device and methods of treatment | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| PL373912A1 (en) | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | |
| MXPA04005980A (es) | Un metodo y dispositivo para reducir dosificacion terapeutica. | |
| ID26861A (id) | Terapi gabungan untuk pengobatan depresi refaktori | |
| EE05056B1 (et) | IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette nhtud ateroskleroosi ravimiseks ja/v?i ennetamiseks | |
| EE200200471A (et) | Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks | |
| ZA200600176B (en) | Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
| EE200000333A (et) | Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod | |
| EE05534B1 (et) | IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks | |
| EE200200694A (et) | Ühendid maopõhja kahjustunud relaksatsiooni raviks, nende valmistamismeetod, farmatseutiline kompositsioon ja selle valmistamismeetod | |
| WO2004006830A3 (en) | Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |